Jazz Pharmaceuticals PLC Total Assets
Jazz Pharmaceuticals PLC total assets. Based on the latest financial reports, Jazz Pharmaceuticals PLC (JAZZ) holds total assets worth $11.86 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Jazz Pharmaceuticals PLC (JAZZ) total market value for the company's overall valuation and market capitalisation.
Total Assets of Jazz Pharmaceuticals PLC (2005–2025)
Total assets of Jazz Pharmaceuticals PLC from 2005 to 2025. This chart illustrates how Jazz Pharmaceuticals PLC's total assets have evolved over time, based on quarterly financial data. See Jazz Pharmaceuticals PLC stock price for real-time trading data and today's change.
Jazz Pharmaceuticals PLC - Asset Composition Analysis
Jazz Pharmaceuticals PLC Total Assets Breakdown (December 2025)
Jazz Pharmaceuticals PLC total assets breakdown as of December 2025. Jazz Pharmaceuticals PLC's total assets of $11.86 Billion consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.9% |
| Accounts Receivable | $830.75 Million | 7.1% |
| Inventory | $416.96 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.43 Billion | 38.0% |
| Goodwill | $1.83 Billion | 15.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Jazz Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Jazz Pharmaceuticals PLC's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jazz Pharmaceuticals PLC's current assets represent 35.7% of total assets in 2025, an increase from 19.1% in 2005.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2025, down from 12.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, a decrease from 70.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 38.0% of total assets.
Jazz Pharmaceuticals PLC Competitors by Total Assets
Key competitors of Jazz Pharmaceuticals PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Jazz Pharmaceuticals PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.04 | 3.38 | 3.35 |
| Quick Ratio | 1.85 | 2.97 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.34 Billion | $2.91 Billion | $2.07 Billion |
Jazz Pharmaceuticals PLC - Advanced Valuation Insights
This section examines the relationship between Jazz Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $11.66 Billion |
| Market Capitalization | $13.55 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Jazz Pharmaceuticals PLC's assets above their book value (1.16x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Jazz Pharmaceuticals PLC's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jazz Pharmaceuticals PLC (2005–2025)
The table below shows the annual total assets of Jazz Pharmaceuticals PLC from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.66 Billion | -2.94% |
| 2024-12-31 | $12.01 Billion | +5.43% |
| 2023-12-31 | $11.39 Billion | +5.15% |
| 2022-12-31 | $10.84 Billion | -11.90% |
| 2021-12-31 | $12.30 Billion | +88.17% |
| 2020-12-31 | $6.54 Billion | +18.00% |
| 2019-12-31 | $5.54 Billion | +6.45% |
| 2018-12-31 | $5.20 Billion | +1.56% |
| 2017-12-31 | $5.12 Billion | +6.74% |
| 2016-12-31 | $4.80 Billion | +42.88% |
| 2015-12-31 | $3.36 Billion | +0.62% |
| 2014-12-31 | $3.34 Billion | +49.18% |
| 2013-12-31 | $2.24 Billion | +13.82% |
| 2012-12-31 | $1.97 Billion | +675.51% |
| 2011-12-31 | $253.57 Million | +86.82% |
| 2010-12-31 | $135.73 Million | +26.38% |
| 2009-12-31 | $107.40 Million | -8.60% |
| 2008-12-31 | $117.50 Million | -43.39% |
| 2007-12-31 | $207.55 Million | -3.27% |
| 2006-12-31 | $214.57 Million | +30.22% |
| 2005-12-31 | $164.78 Million | -- |
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more